Skip to main content
main-content

01.12.2014 | Clinical Study | Ausgabe 3/2014

Journal of Neuro-Oncology 3/2014

1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors

Zeitschrift:
Journal of Neuro-Oncology > Ausgabe 3/2014
Autoren:
Haihui Jiang, Zhe Zhang, Xiaohui Ren, Wei Zeng, Wenqing Jia, Junmei Wang, Song Lin
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s11060-014-1593-0) contains supplementary material, which is available to authorized users.

Abstract

The subjectivity in pathological diagnosis of anaplastic oligoastrocytoma (AOA) and uncertainty in designation of glioblastoma with oligodendroglioma component (GBMO) were two major dilemmas which puzzled neuro-pathologists and neurosurgeons. The present study was designed to project a molecular classification scheme based on the status of chromosome 1p and 19q. Patients (n = 117) with histological diagnosis of primary high-grade oligodendroglial tumors (HGOs) enrolled in the study. Fluorescence in situ hybridization (FISH) for chromosomes 1p and 19q was performed. Univariate analysis showed that higher tumor grade, 1p/19q maintenance and 1q/19p co polysomy were confirmed as risk factors in HGOs (P < 0.01). Accordingly, patients with HGOs were divided into four subtypes which conferred remarkably distinct prognosis based on the number of risk factors (0 risk factor: HGOs-1, 1 risk factor: HGOs-2, 2 risk factors: HGOs-3, 3 risk factors: HGOs-4). Cox regression model revealed that the tumor grade was no longer independently associated with survival, while the molecular classification scheme showed a marked prognostic significance (HR = 0.359, 95 % CI 0.261–0.494, P < 0.001 for progression-free survival (PFS); HR = 0.393, 95 % CI 0.283–0.546, P < 0.001 for overall survival (OS)). The classification scheme incorporating traditional pathology with molecular information can be served as a supplement of the current WHO classification system and contribute to the personalized treatment decision-making.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (TIFF 195 kb) Kaplan–Meier plots of the series of 117 HGOs showing the association of 1p/19q codeletion with progression-free survival A and overall survival B; 1q/19p copolysomy with progression-free survival C and overall survival D; tumor grade with progression-free survival E and overall survival F
11060_2014_1593_MOESM1_ESM.tif
Supplementary material 2 (DOC 42 kb)
11060_2014_1593_MOESM2_ESM.doc
Supplementary material 3 (DOC 31 kb)
11060_2014_1593_MOESM3_ESM.doc
Supplementary material 4 (DOC 31 kb)
11060_2014_1593_MOESM4_ESM.doc
Supplementary material 5 (DOC 31 kb)
11060_2014_1593_MOESM5_ESM.doc
Supplementary material 6 (DOC 32 kb)
11060_2014_1593_MOESM6_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2014

Journal of Neuro-Oncology 3/2014 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise